The CCDC71L Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to eliminate expression of the CCDC71L gene in the human renal cell adenocarcinoma line 786-O. This product provides a pooled population of knockout cells generated by transient introduction of CRISPR/Cas9 components targeting CCDC71L, resulting in a heterogeneous mixture of gene-disrupted alleles. As a polyclonal knockout, it is ideally suited for initial functional screening and bulk assays where clonal isolation is not required, enabling rapid assessment of CCDC71L loss-of-function phenotypes.
The host cell line 786-O is an established epithelial model derived from a primary clear cell renal cell carcinoma, a common and aggressive form of kidney cancer. It retains key characteristics of renal cell carcinoma, including aberrant VHL and mTOR pathway activity, making it a valuable system for studying tumor biology and therapeutic responses. This background provides a clinically relevant context to investigate the contribution of CCDC71L to renal cancer pathogenesis and its potential as a drug target.
CCDC71L encodes a coiled-coil domain-containing protein, a structural motif known to mediate protein-protein interactions and facilitate the assembly of macromolecular complexes. While the specific molecular partners and signaling pathways involving CCDC71L remain largely uncharacterized, its domain architecture suggests a role in organizing multiprotein networks that may influence cellular architecture, vesicle trafficking, or signal transduction. Disruption of CCDC71L in 786-O cells is expected to perturb these interaction networks, offering a loss-of-function model to elucidate its cellular functions through comparative analysis with wild-type controls.
In the context of renal cell carcinoma, the functional significance of CCDC71L is still undefined. The 786-O knockout cells enable systematic investigation of whether CCDC71L contributes to hallmark cancer phenotypes such as uncontrolled proliferation, migration, and colony-forming potential. By comparing polyclonal knockout populations to parental 786-O cells in standard assays, researchers can explore the gene??s impact on tumorigenic behavior and identify downstream pathway alterations, thereby clarifying its role in renal cell carcinoma biology.
This polyclonal knockout model is optimized for a wide range of research applications, including loss-of-function phenotypic screening, protein-protein interaction studies via co-immunoprecipitation, and transcriptomic analysis by RNA-seq. Typical downstream characterization employs Western blotting and RT-qPCR to confirm CCDC71L ablation, immunofluorescence to assess subcellular localization of interacting proteins, and functional assays such as colony formation, migration, and proliferation assays to quantify oncogenic properties. The product serves as a versatile tool for academic and pharmaceutical researchers investigating CCDC71L biology and its therapeutic relevance in renal cell carcinoma. For additional information, please contact Ascent Research.
